Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Subcutaneous Tocilizumab (MRA-SC) in Takayasu Arteritis
jRCT2080222565Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Takayasu arteritis (TAK) comparing Tocilizumab 162 mg SC weekly with Placebo SC weekly (2 arms). Started Jul 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on jRCT2080222565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222565.